Application of type I collagen / Slc7a11 regulatory axis in vascular remodeling
By inhibiting type I collagen and solute carrier cysteine transporter and reducing foam cell production, the problem of vascular remodeling after organ transplantation is solved, and the utilization rate and function of transplanted organs are improved.
Patent Information
- Application Number
- CN202411403095.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-09
- Publication Date
- 2024-11-22
AI Technical Summary
Vascular remodeling after organ transplantation leads to failure of transplanted organs, and the existing technology is difficult to effectively prevent and treat, resulting in low utilization of transplanted organs and death of patients.
By inhibiting the type I collagen and solute carrier cystin transporter, blocking its expression and activity in macrophages, thereby reducing foam cell production and vascular remodeling, siRNA, Erastin and SB525334 were used to intervene.
It significantly alleviated foam cell production 14 days after organ transplantation and vascular remodeling 28 days, improved the function of transplanted organs, and improved the utilization rate of transplanted organs.
Smart Images

Figure HDA0005075796970000011 
Figure HDA0005075796970000021 
Figure HDA0005075796970000031
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology and relates to the application of type I collagen / Slc7a11 regulatory axis in vascular remodeling. Background Art
[0002] Vascular remodeling refers to the structural and functional changes that occur in blood vessels to adapt to changes in the internal and external environment, including cell biological changes such as proliferation, hypertrophy, apoptosis, cell migration, production and degradation of extracellular matrix in vascular wall cells. Vascular remodeling is an important pathological basis for the deterioration of many vascular-related diseases (such as transplant rejection, atherosclerosis and hypertension) and is also the cause of the occurrence and development of such diseases.
[0003] Organ transplantation-related immune rejection is the most important pathological reaction that promotes the progression of organ transplantation failure. Currently, the main measures for organ transplantation rejection in clinical practice are exogenous administration of glucocorticoids and interferon inhibitors to inhibit systemic inflammatory responses, but the rate of transplanted organ failure remains high.
[0004] Type I collagen is a heterotrimeric molecule, each chain is composed of more than 1000 amino acids, and collagen trimers have high tensile strength. Type I collagen mainly maintains the integrity of organs and tissues and ensures their normal function. At the same time, type I collagen also has functions such as signal transduction, transportation of growth factors and cytokines. This allows type I collagen to play a corresponding role in pathological and physiological processes such as aging and inflammatory response, but the role of type I collagen in organ immune rejection has not been reported. The solute carrier cystine transporter (Slc7a11) is one of the most critical upstream regulators of cell ferroptosis. It mainly promotes the influx of cystine to reduce intracellular reactive oxygen species and thus inhibit the process of cell ferroptosis. Inhibiting Slc7a11 can promote tumor cell ferroptosis and improve the long-term prognosis of some tumor patients. However, the role of Slc7a11 in organ transplant immune rejection and whether it is regulated by Col1a1 is still unknown. Summary of the invention
[0005] Organ transplantation is currently the most effective treatment for patients with end-stage organ failure, but graft vascular remodeling is the main cause of long-term graft failure and patient death. WHO data show that the number of organ transplants each year only meets 10% of global demand. However, the main cause of transplant organ failure is vascular remodeling caused by immune rejection. Therefore, the prevention and treatment of post-transplant vascular remodeling is the key to improving the utilization rate of transplanted organs in the current context of scarcity of transplanted organs.
[0006] The inventors' experimental studies have found that foam cells are generated in large quantities in the early stages of organ transplant blood vessels. Foam cell generation is the most typical pathological change in vascular lesions. The large amount of foam cell generation leads to vascular remodeling and reduced tissue blood supply, which is the main pathological feature of ischemia-related diseases. The inventors' experimental studies have found that in the early stages of organ transplant blood vessels, there is a large amount of type I collagen accompanied by foam cell generation. In vitro experiments have shown that the intracellular lipid content of macrophages after type I collagen intervention increased significantly and showed foam-like changes, which proves that type I collagen can promote macrophage foaming. In order to further study the mechanism by which type I collagen promotes foam cell generation, the inventors' in vitro studies have found that type I collagen can promote the expression of macrophage membrane Slc7a11. After the inventors constructed siRNA-Slc7a11 to silence the expression of macrophage Slc7a11, the effect of type I collagen in promoting foam cell generation disappeared, indicating that type I collagen promotes the generation of giant foam cells by regulating the generation of Slc7a11 on the surface of macrophage membranes. To further verify this conclusion, the inventors conducted type I collagen and Slc7a11 inhibition experiments in mice and found that inhibition of type I collagen or Slc7a11 could significantly reduce foam cell generation 14 days after organ vascular transplantation in mice and organ transplant vascular remodeling 28 days after transplantation.
[0007] In a first aspect, the present invention provides the use of a type I collagen inhibitor and / or a solute carrier cystine transporter inhibitor in the preparation of a product for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases.
[0008] In some embodiments, in the above application, the type I collagen inhibitor has one or more of the following functions:
[0009] (1) Inhibit the expression and / or activity of type I collagen;
[0010] (2) inhibiting the expression of genes encoding type I collagen;
[0011] The solute carrier cystine transporter inhibitor has one or more of the following functions:
[0012] (1) inhibiting the expression and / or activity of the solute carrier cystine transporter;
[0013] (2) Inhibit the expression of the gene encoding the solute carrier cystine transporter.
[0014] In some embodiments, in any of the above-mentioned uses, the type I collagen is type I collagen α1, ie, Col1a1.
[0015] In some embodiments, Col1a1 is human Col1a1, whose amino acid sequence has the NCBI accession number of NP_000079.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto; in some embodiments, Col1a1 is mouse Col1a1, whose amino acid sequence has the NCBI accession number of NP_031768.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto.
[0016] In some embodiments, in any of the above-mentioned applications, the type I collagen encoding gene includes a DNA sequence encoding type I collagen, a pre-mRNA sequence transcribed from the DNA encoding type I collagen (including genomic DNA with introns and exons), and an mRNA sequence encoding type I collagen. In some embodiments, the type I collagen encoding gene is Col1a1 mRNA. In some embodiments, the Col1a1 mRNA is human Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_000088.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Col1a1. In some embodiments, the Col1a1 mRNA is mouse Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_007742.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Col1a1.
[0017] In some embodiments, in any of the above-mentioned applications, the solute carrier cystine transporter is (solute carrier family 7 member 11) Slc7a11 (also known as xCT), which is an important subunit of the Xc-system and synthesizes glutathione by transporting extracellular cystine into cells.
[0018] In some embodiments, Slc7a11 is human Slc7a11, whose amino acid sequence has the NCBI accession number of NP_055146.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto; in some embodiments, Slc7a11 is mouse Slc7a11, whose amino acid sequence has the NCBI accession number of NP_036120.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto.
[0019] In some embodiments, in any of the above-mentioned applications, the solute carrier cystine transporter encoding gene includes a DNA sequence encoding a solute carrier cystine transporter, a pre-mRNA sequence transcribed from a DNA encoding a solute carrier cystine transporter (including genomic DNA of introns and exons), and an mRNA sequence encoding a solute carrier cystine transporter. In some embodiments, the solute carrier cystine transporter encoding gene is Slc7a11mRNA. In some embodiments, the Slc7a11 mRNA is human Slc7a11 mRNA, and the NCBI accession number of its nucleic acid sequence is NM_014331.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Slc7a11. In some embodiments, the Slc7a11 mRNA is mouse Slc7a11mRNA, and the NCBI accession number of its nucleic acid sequence is NM_011990.2, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Slc7a11.
[0020] In some embodiments, in any of the above-mentioned applications, the type I collagen inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, small molecule compounds (such as SB525334, UK383367) against type I collagen; wherein the nucleic acid is a small interfering RNA, dsRNA, microRNA, antisense nucleic acid or gene editing vector (such as CRISPR-Cas9 gene editing vector or TALEN gene editing vector) with type I collagen or its transcript as the target sequence and capable of inhibiting type I collagen expression or gene transcription.
[0021] In some embodiments, in any of the above-mentioned applications, the solute carrier cystine transporter inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids (e.g., siRNA-Slc7a11 herein composed of SEQ ID NO: 1 and SEQ ID NO: 2), small molecule compounds (e.g., Erastin, HG106) against the solute carrier cystine transporter, wherein the nucleic acid is a small interfering RNA, dsRNA, microRNA, antisense nucleic acid, or gene editing vector (e.g., CRISPR-Cas9 gene editing vector or TALEN gene editing vector) that targets the solute carrier cystine transporter or its transcript and can inhibit the expression or gene transcription of the solute carrier cystine transporter.
[0022] In some embodiments, in any of the above uses, the vascular remodeling is vascular remodeling associated with a vascular-related disease or condition;
[0023] Preferably, the disease or condition is selected from vascular wall damage (such as physical damage caused by interventional stents, vascular damage caused by atherosclerosis, vascular damage caused by hyperlipidemia, vascular damage caused by hypertension, vascular damage caused by diabetes, and vascular damage caused by autoimmune diseases), vascular stenosis after injury, blood flow dysfunction after injury, thrombosis, vascular stenosis after PCI and Bypass surgery, atherosclerosis, cerebral infarction, transplant vascular lesions after allogeneic transplantation, transplant rejection, diabetic microangiopathy, cerebrovascular disease, and any combination thereof.
[0024] In a second aspect, the present invention provides the following uses of type I collagen or its encoding gene as a biomarker or target, an agent for detecting the type I collagen or its encoding gene, a solute carrier cystine transporter or its encoding gene as a biomarker or target and / or an agent for detecting the solute carrier cystine transporter or its encoding gene:
[0025] i. Application in screening for vascular remodeling and / or diseases related to vascular remodeling or in preparing products for screening for vascular remodeling and / or diseases related to vascular remodeling;
[0026] ii. Application in evaluating vascular remodeling and / or vascular remodeling-related diseases or in preparing products for evaluating vascular remodeling and / or vascular remodeling-related diseases;
[0027] iii. Application in the preparation of products for diagnosing vascular remodeling and / or vascular remodeling-related diseases;
[0028] iv. Application in screening and / or preparing products for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases;
[0029] v. Application in monitoring the course of vascular remodeling and / or vascular remodeling-related diseases or in preparing products for monitoring the course of vascular remodeling and / or vascular remodeling-related diseases;
[0030] vi. Application in analyzing vascular remodeling and / or the prognosis of diseases related to vascular remodeling or in preparing products for analyzing vascular remodeling and / or the prognosis of diseases related to vascular remodeling;
[0031] vii. Use in inhibiting foam cell formation or preparing products for inhibiting foam cell formation.
[0032] In some embodiments, in the above-mentioned application, the reagent for detecting the type I collagen or its encoding gene is a reagent for detecting the expression amount and / or activity level of the type I collagen and / or a reagent for detecting the mRNA expression amount of the type I collagen encoding gene; for example, a reagent for detecting the mRNA expression level of the type I collagen encoding gene (for example, a primer composition that specifically amplifies the gene, a probe that specifically recognizes the gene), a reagent for detecting the expression level of type I collagen (for example, an antibody, an aptamer, a dye).
[0033] In some embodiments, in the above application, the reagent for detecting the solute carrier cystine transporter or its encoding gene is a reagent for detecting the expression amount and / or activity level of the solute carrier cystine transporter and / or a reagent for detecting the mRNA expression amount of the solute carrier cystine transporter encoding gene; for example, a reagent for detecting the mRNA expression level of the solute carrier cystine transporter encoding gene (for example, a primer composition that specifically amplifies the gene, a probe that specifically recognizes the gene), a reagent for detecting the expression level of the solute carrier cystine transporter (for example, an antibody, an aptamer, a dye).
[0034] In some embodiments, in the above application, the reagents include reagents for detecting the expression amount of the biomarker by PCR, flow cytometry, enzyme-linked immunosorbent assay, immunofluorescence, radioimmunoassay, immunocoprecipitation, immunoblotting, high performance liquid chromatography, capillary gel electrophoresis, near infrared spectroscopy, mass spectrometry, immunochemiluminescence, colloidal gold immunoassay, fluorescent immunochromatography, surface plasmon resonance, immuno-PCR or biotin-avidin technology.
[0035] In some embodiments, in any of the above-mentioned uses, the type I collagen is type I collagen α1, ie, Col1a1.
[0036] In some embodiments, Col1a1 is human Col1a1, whose amino acid sequence has the NCBI accession number of NP_000079.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto; in some embodiments, Col1a1 is mouse Col1a1, whose amino acid sequence has the NCBI accession number of NP_031768.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto.
[0037] In some embodiments, in any of the above-mentioned applications, the type I collagen encoding gene includes a DNA sequence encoding type I collagen, a pre-mRNA sequence transcribed from the DNA encoding type I collagen (including genomic DNA with introns and exons), and an mRNA sequence encoding type I collagen. In some embodiments, the type I collagen encoding gene is Col1a1 mRNA. In some embodiments, the Col1a1 mRNA is human Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_000088.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Col1a1. In some embodiments, the Col1a1 mRNA is mouse Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_007742.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Col1a1.
[0038] In some embodiments, in any of the above-mentioned applications, the solute carrier cystine transporter is (solute carrier family 7 member 11) Slc7a11 (also known as xCT), which is an important subunit of the Xc-system and synthesizes glutathione by transporting extracellular cystine into cells.
[0039] In some embodiments, Slc7a11 is human Slc7a11, whose amino acid sequence has the NCBI accession number of NP_055146.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto; in some embodiments, Slc7a11 is mouse Slc7a11, whose amino acid sequence has the NCBI accession number of NP_036120.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto.
[0040] In some embodiments, in any of the above-mentioned applications, the solute carrier cystine transporter encoding gene includes a DNA sequence encoding a solute carrier cystine transporter, a pre-mRNA sequence transcribed from a DNA encoding a solute carrier cystine transporter (including genomic DNA of introns and exons), and an mRNA sequence encoding a solute carrier cystine transporter. In some embodiments, the solute carrier cystine transporter encoding gene is Slc7a11mRNA. In some embodiments, the Slc7a11 mRNA is human Slc7a11 mRNA, and the NCBI accession number of its nucleic acid sequence is NM_014331.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Slc7a11. In some embodiments, the Slc7a11 mRNA is mouse Slc7a11mRNA, and the NCBI accession number of its nucleic acid sequence is NM_011990.2, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Slc7a11.
[0041] In some embodiments, in any of the above applications, the expression level of type I collagen encoding gene, the expression level or activity of type I collagen in patients with vascular remodeling and / or vascular remodeling-related diseases is increased compared with a normal control group; and / or
[0042] The expression level of the solute carrier cystine transporter encoding gene, the expression level or activity of the solute carrier cystine transporter in patients with vascular remodeling and / or vascular remodeling-related diseases is increased compared with that in a normal control group.
[0043] In some embodiments, in any of the above uses, the vascular remodeling is vascular remodeling associated with a vascular-related disease or condition;
[0044] Preferably, the disease or condition is selected from vascular wall damage (such as physical damage caused by interventional stents, vascular damage caused by atherosclerosis, vascular damage caused by hyperlipidemia, vascular damage caused by hypertension, vascular damage caused by diabetes, and vascular damage caused by autoimmune diseases), vascular stenosis after injury, blood flow dysfunction after injury, thrombosis, vascular stenosis after PCI and Bypass surgery, atherosclerosis, cerebral infarction, transplant vascular lesions after allogeneic transplantation, transplant rejection, diabetic microangiopathy, cerebrovascular disease, and any combination thereof.
[0045] In a third aspect, the present invention provides a method for screening drugs for preventing, treating and / or alleviating vascular remodeling and / or diseases related to vascular remodeling, comprising: selecting a substance that inhibits type I collagen and / or a substance that inhibits the solute carrier cystine transporter from the compounds to be screened as a drug for preventing, treating and / or alleviating vascular remodeling and / or diseases related to vascular remodeling.
[0046] In some embodiments, in the above method, the substance that inhibits type I collagen has one or more of the following functions:
[0047] (1) Inhibit the expression and / or activity of type I collagen;
[0048] (2) inhibiting the expression of genes encoding type I collagen;
[0049] The substance that inhibits the solute carrier cystine transporter has one or more of the following functions:
[0050] (1) inhibiting the expression and / or activity of the solute carrier cystine transporter;
[0051] (2) Inhibit the expression of the gene encoding the solute carrier cystine transporter.
[0052] In some embodiments, in any of the above methods, the type I collagen is type I collagen α1, ie, Col1a1.
[0053] In some embodiments, Col1a1 is human Col1a1, whose amino acid sequence has the NCBI accession number of NP_000079.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto; in some embodiments, Col1a1 is mouse Col1a1, whose amino acid sequence has the NCBI accession number of NP_031768.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto.
[0054] In some embodiments, in any of the methods described above, the type I collagen encoding gene includes a DNA sequence encoding type I collagen, a pre-mRNA sequence transcribed from the DNA encoding type I collagen (including genomic DNA with introns and exons), and an mRNA sequence encoding type I collagen. In some embodiments, the type I collagen encoding gene is Col1a1 mRNA. In some embodiments, the Col1a1 mRNA is human Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_000088.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-described Col1a1. In some embodiments, the Col1a1 mRNA is mouse Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_007742.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-described Col1a1.
[0055] In some embodiments, in any of the methods described above, the solute carrier cystine transporter is (solute carrier family 7 member 11) Slc7a11 (also known as xCT), which is an important subunit of the Xc-system and synthesizes glutathione by transporting extracellular cystine into cells.
[0056] In some embodiments, Slc7a11 is human Slc7a11, whose amino acid sequence has the NCBI accession number of NP_055146.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto; in some embodiments, Slc7a11 is mouse Slc7a11, whose amino acid sequence has the NCBI accession number of NP_036120.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto.
[0057] In some embodiments, in any of the above methods, the solute carrier cystine transporter encoding gene includes a DNA sequence encoding a solute carrier cystine transporter, a pre-mRNA sequence transcribed from a DNA encoding a solute carrier cystine transporter (including genomic DNA of introns and exons), and an mRNA sequence encoding a solute carrier cystine transporter. In some embodiments, the solute carrier cystine transporter encoding gene is Slc7a11mRNA. In some embodiments, the Slc7a11 mRNA is human Slc7a11 mRNA, and the NCBI accession number of its nucleic acid sequence is NM_014331.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-described Slc7a11. In some embodiments, the Slc7a11 mRNA is mouse Slc7a11mRNA, and the NCBI accession number of its nucleic acid sequence is NM_011990.2, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-described Slc7a11.
[0058] In some embodiments, in any of the above methods, the vascular remodeling is vascular remodeling associated with a vascular-related disease or condition;
[0059] Preferably, the disease or condition is selected from vascular wall damage (such as physical damage caused by interventional stents, vascular damage caused by atherosclerosis, vascular damage caused by hyperlipidemia, vascular damage caused by hypertension, vascular damage caused by diabetes, and vascular damage caused by autoimmune diseases), vascular stenosis after injury, blood flow dysfunction after injury, thrombosis, vascular stenosis after PCI and Bypass surgery, atherosclerosis, cerebral infarction, transplant vascular lesions after allogeneic transplantation, transplant rejection, diabetic microangiopathy, cerebrovascular disease, and any combination thereof.
[0060] In a fourth aspect, the present invention provides a product comprising or coated with an effective amount of a type I collagen inhibitor and / or a solute carrier cystine transporter inhibitor.
[0061] In some embodiments, in the above product, the type I collagen inhibitor has one or more of the following functions:
[0062] (1) Inhibit the expression and / or activity of type I collagen;
[0063] (2) inhibiting the expression of genes encoding type I collagen;
[0064] The solute carrier cystine transporter inhibitor has one or more of the following functions:
[0065] (1) inhibiting the expression and / or activity of the solute carrier cystine transporter;
[0066] (2) Inhibit the expression of the gene encoding the solute carrier cystine transporter.
[0067] In some embodiments, in any of the above products, the type I collagen is type I collagen α1, ie, Col1a1.
[0068] In some embodiments, Col1a1 is human Col1a1, whose amino acid sequence has the NCBI accession number of NP_000079.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto; in some embodiments, Col1a1 is mouse Col1a1, whose amino acid sequence has the NCBI accession number of NP_031768.2, or an amino acid sequence having at least 80% sequence identity thereto and having Col1a1 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Col1a1 activity compared thereto.
[0069] In some embodiments, in any of the above products, the type I collagen encoding gene includes a DNA sequence encoding type I collagen, a pre-mRNA sequence transcribed from the DNA encoding type I collagen (including genomic DNA with introns and exons), and an mRNA sequence encoding type I collagen. In some embodiments, the type I collagen encoding gene is Col1a1 mRNA. In some embodiments, the Col1a1 mRNA is human Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_000088.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above Col1a1. In some embodiments, the Col1a1 mRNA is mouse Col1a1 mRNA, the NCBI accession number of its nucleic acid sequence is NM_007742.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above Col1a1.
[0070] In some embodiments, in any of the above products, the solute carrier cystine transporter is (solute carrier family 7 member 11) Slc7a11 (also known as xCT), which is an important subunit of the Xc-system and synthesizes glutathione by transporting extracellular cystine into cells.
[0071] In some embodiments, Slc7a11 is human Slc7a11, whose amino acid sequence has the NCBI accession number of NP_055146.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto; in some embodiments, Slc7a11 is mouse Slc7a11, whose amino acid sequence has the NCBI accession number of NP_036120.1, or an amino acid sequence having at least 80% sequence identity thereto and having Slc7a11 activity, or a sequence having one or more amino acid substitutions (e.g., conservative substitutions), deletions or insertions, or any combination thereof, and having Slc7a11 activity compared thereto.
[0072] In some embodiments, in any of the above-mentioned products, the solute carrier cystine transporter encoding gene includes a DNA sequence encoding a solute carrier cystine transporter, a pre-mRNA sequence transcribed from a DNA encoding a solute carrier cystine transporter (including genomic DNA of introns and exons), and an mRNA sequence encoding a solute carrier cystine transporter. In some embodiments, the solute carrier cystine transporter encoding gene is Slc7a11mRNA. In some embodiments, the Slc7a11 mRNA is human Slc7a11 mRNA, and the NCBI accession number of its nucleic acid sequence is NM_014331.4, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Slc7a11. In some embodiments, the Slc7a11 mRNA is mouse Slc7a11mRNA, and the NCBI accession number of its nucleic acid sequence is NM_011990.2, or a nucleic acid molecule having at least 80% sequence identity therewith and encoding any of the above-mentioned Slc7a11.
[0073] In some embodiments, in any of the above-mentioned products, the type I collagen inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, small molecule compounds (such as SB525334, UK383367) against type I collagen; wherein the nucleic acid is a small interfering RNA, dsRNA, microRNA, antisense nucleic acid or gene editing vector (such as CRISPR-Cas9 gene editing vector or TALEN gene editing vector) that has type I collagen or its transcript as the target sequence and can inhibit type I collagen expression or gene transcription.
[0074] In some embodiments, in any of the above-mentioned products, the solute carrier cystine transporter inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids (e.g., siRNA-Slc7a11 herein composed of SEQ ID NO: 1 and SEQ ID NO: 2), and small molecule compounds (e.g., Erastin, HG106) against the solute carrier cystine transporter; wherein the nucleic acid is a small interfering RNA, dsRNA, microRNA, antisense nucleic acid, or gene editing vector (e.g., CRISPR-Cas9 gene editing vector or TALEN gene editing vector) that targets the solute carrier cystine transporter or its transcript and is capable of inhibiting the expression or gene transcription of the solute carrier cystine transporter.
[0075] In some embodiments, the product is a vascular stent or a catheter with a balloon, and the type I collagen inhibitor and / or the solute carrier cystine transporter inhibitor may be contained in the coating of the vascular stent or the balloon.
[0076] In some embodiments, the product is a pharmaceutical composition comprising the type I collagen inhibitor and / or the solute carrier cystine transporter inhibitor as active ingredients, optionally further comprising pharmaceutically acceptable excipients.
[0077] In some embodiments, in any of the above products, the product is used to prevent, treat and / or alleviate vascular remodeling and / or vascular remodeling-related diseases;
[0078] The vascular remodeling is vascular remodeling associated with a vascular-related disease or condition;
[0079] Preferably, the disease or condition is selected from vascular wall damage (such as physical damage caused by interventional stents, vascular damage caused by atherosclerosis, vascular damage caused by hyperlipidemia, vascular damage caused by hypertension, vascular damage caused by diabetes, and vascular damage caused by autoimmune diseases), vascular stenosis after injury, blood flow dysfunction after injury, thrombosis, vascular stenosis after PCI and Bypass surgery, atherosclerosis, cerebral infarction, transplant vascular lesions after allogeneic transplantation, transplant rejection, diabetic microangiopathy, cerebrovascular disease, and any combination thereof.
[0080] Compared with the prior art, the present invention has the following beneficial effects:
[0081] The present invention has discovered potential biomarkers for judging the progress of organ transplant immune rejection reaction - type I collagen and Slc7a11. The inventor has found that type I collagen, Slc7a11 and foam cells accumulate in large quantities in vascular tissues as the transplant immune rejection reaction of transplanted organs develops. In vitro studies have found that type I collagen intervention in macrophages can promote the expression of Slc7a11 and lead to macrophage foaming, ultimately leading to vascular intimal hyperplasia, which is closely related to the important pathological sign of the development of organ transplant immune rejection reaction - transplant organ vascular remodeling. The present invention proposes to use type I collagen and solute carrier cystine transporter as biomarkers for judging the progression of vascular remodeling and vascular remodeling-related diseases (especially organ transplant immune rejection reaction) or to use type I collagen and solute carrier cystine transporter as targets for preventing, treating and / or alleviating vascular remodeling and vascular remodeling-related diseases (especially organ transplant rejection reaction). The present invention provides a new idea for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases, and can be particularly used for preventing, treating and / or alleviating organ transplant rejection reaction, improving transplant organ failure, and increasing the utilization rate of transplant organs. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1In the figure, A is the Sirius red staining image of the aorta of the control group mice and the transplanted aorta of the transplanted group mice at 2 weeks after surgery (under 200× and 400× fields of view, respectively); B is the statistical bar graph of the type I collagen content in the control group and the transplanted group obtained based on the Sirius red staining results; C is the BODIPY fluorescence staining image of macrophages in the type I collagen intervention group (type I collagen (+)) and the control group (type I collagen (-)); D is the proportion of BODIPY positive cells in the type I collagen intervention group (type I collagen (+)) and the control group (type I collagen (-)); the results showed that there was a large amount of type I collagen in the blood vessels of the transplanted organs and type I collagen promoted the differentiation of macrophages into foam cells.
[0083] Figure 2 In the figure, A is the flow cytometer detection of Slc7a11 signal intensity in the type I collagen intervention group and the control group; B is the Slc7a11 fluorescence intensity in the type I collagen intervention group and the control group; C is the Slc7a11 fluorescence staining image in the type I collagen intervention group and the control group; D is the proportion of cell membrane Slc7a11 positive cells in the type I collagen intervention group and the control group; the results showed that type I collagen promoted the expression of solute carrier cystine transporter on the macrophage membrane.
[0084] Figure 3 In the figure, A is the BODIPY staining image of the type I collagen intervention group (type I collagen (+)) and the non-collagen intervention group (type I collagen (-)) in the siRNA-Slc7a11 transfection group, the anti-Slc7a11 group and the control group; B is the proportion of BODIPY positive cells in the type I collagen intervention group (type I collagen (+)) and the non-collagen intervention group (type I collagen (-)) in the siRNA-Slc7a11 transfection group, the anti-Slc7a11 group and the control group; in vitro experiments have shown that inhibiting cystine transporter can reduce the formation of foam cells.
[0085] Figure 4 A is the F4 / 80, BODIPY and DAPI staining images of the graft vessels in the control group, anti-type I collagen group and anti-Slc7a11 group 2 weeks after transplantation; B is the HE staining image of the graft vessels in the control group, anti-type I collagen group and anti-Slc7a11 group 4 weeks after transplantation; C is the intima-to-media (I / M) ratio of the control group, anti-type I collagen group and anti-Slc7a11 group by HE staining; in vivo experiments have shown that inhibiting type I collagen production or inhibiting Slc7a11 protein can significantly improve vascular remodeling of transplanted organs. DETAILED DESCRIPTION
[0086] The present disclosure is further described below in conjunction with specific embodiments. In the following description, many specific details are set forth to facilitate a full understanding of the present disclosure. However, the present disclosure can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present disclosure, so the present disclosure is not limited by the specific embodiments disclosed below.
[0087] Unless otherwise specified, the technical means used in the examples are all routine operations in the art, or according to the experimental methods recommended by the kit and instrument manufacturers. The reagents and biological materials used in the examples can be obtained from commercial channels unless otherwise specified.
[0088] Unless otherwise defined, all technical and scientific terms used in the present disclosure have the same meanings as those commonly understood by those skilled in the art in the art of the present disclosure. The terms used in the present specification are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0089] Herein, the terms “comprises,” “comprising,” or “containing” should be understood to mean the inclusion of specified components but not the exclusion of any other components.
[0090] As used herein, the term "about" refers to a value within an acceptable error range for a particular value determined by a person of ordinary skill in the art, which value depends in part on how it is measured or determined (i.e., the limits of the measurement system). Alternatively, "about" may mean a range of up to ±20%, such as ±10%, ±5%, or ±1%. Unless otherwise indicated, when a particular value appears in this application, the meaning of "about" should be assumed to be within an acceptable error range for that particular value.
[0091] The term "type I collagen" refers to type I collagen or its protein branches, such as Col1a1, Col1a2, and the like.
[0092] The term "solute carrier cystine transporter" refers to a cystine transporter or a complex protein containing a cystine transporter, such as Slc7a11 and the like.
[0093] The term "foam cells" mainly refers to macrophages that have phagocytosed lipids. These cells phagocytize large amounts of lipids, and the cytoplasm is filled with lipids to form a foamy state, hence the name foam cells.
[0094] The term "gene encoding type I collagen" refers to any polynucleotide encoding type I collagen. For example, it includes DNA sequences encoding type I collagen, pre-mRNA sequences transcribed from DNA encoding type I collagen (including genomic DNA of introns and exons), and mRNA sequences encoding type I collagen. "Col1a1 mRNA" refers to mRNA encoding Col1a1 protein.
[0095] Examples of sequences of human Col1a1 and Col1a1 mRNA, mouse Col1a1 and Col1a1 mRNA, or Col1a1 and Col1a1 mRNA of other species can be easily obtained using publicly available databases (eg, NCBI, Gene cards, etc.).
[0096] The term "solute carrier cystine transporter encoding gene" refers to any polynucleotide encoding a solute carrier cystine transporter. For example, it includes a DNA sequence encoding a solute carrier cystine transporter, a pre-mRNA sequence transcribed from a DNA encoding a solute carrier cystine transporter (including genomic DNA of introns and exons), and an mRNA sequence encoding a solute carrier cystine transporter. "Slc7a11 mRNA" refers to an mRNA encoding a Slc7a11 protein.
[0097] Examples of sequences of human Slc7a11 and Slc7a11 mRNA, mouse Slc7a11 and Slc7a11 mRNA, or Slc7a11 and Slc7a11 mRNA of other species can be readily obtained using publicly available databases (eg, NCBI, Gene cards, etc.).
[0098] In this article, the term "type I collagen inhibitor" means that under the same conditions, the expression level and / or activity level of type I collagen in cells treated with the inhibitor is reduced, or the expression level of the type I collagen encoding gene is reduced, compared with cells not treated with the inhibitor, which can lead to, for example, reduced foam cell formation, reduced vascular remodeling (e.g., a reduced intima-to-media ratio), reduced transplant rejection, etc.
[0099] Herein, the phrase "inhibiting the expression and / or activity of type I collagen" includes inhibiting the expression and / or activity of any type I collagen (such as mouse type I collagen, rat type I collagen, monkey type I collagen or human type I collagen) or its mutants; the phrase "inhibiting the expression of a gene encoding type I collagen" includes inhibiting the expression of any gene encoding type I collagen or its mutants.
[0100] As used herein, the term "solute carrier cystine transporter inhibitor" means that, under the same conditions, the expression level and / or activity level of the solute carrier cystine transporter in cells treated with the inhibitor is reduced, or the expression level of the gene encoding the solute carrier cystine transporter is reduced, compared with cells not treated with the inhibitor, which can lead to, for example, reduced foam cell formation, reduced vascular remodeling (e.g., reduced intima-to-media ratio), reduced transplant rejection, etc.
[0101] Herein, the phrase "inhibiting the expression and / or activity of a solute carrier cystine transporter" includes inhibiting the expression and / or activity of any solute carrier cystine transporter (such as a mouse solute carrier cystine transporter, a rat solute carrier cystine transporter, a monkey solute carrier cystine transporter or a human solute carrier cystine transporter) or a mutant thereof; the phrase "inhibiting the expression of a solute carrier cystine transporter encoding gene" includes inhibiting the expression of any gene encoding a solute carrier cystine transporter or a mutant thereof.
[0102] Inhibition includes any level of inhibition. In certain embodiments, the inhibition is at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
[0103] Gene expression can be assessed based on any variable level related to gene expression, such as mRNA level or protein level. Inhibition can be assessed by the reduction of one or more absolute or relative levels compared to control levels in these variables. Control level can be any type of control level used in the art, such as baseline level before administration or from a similar untreated or controlled (e.g., only buffer control or inert agent control) treated subject, cell or sample level determined.
[0104] As used herein, the term "vascular remodeling associated with a vascular-related disease or condition" means that a vascular-related disease or condition is caused by vascular remodeling, or that vascular remodeling is caused by a vascular-related disease or condition.
[0105] In this article, the term "vascular remodeling" refers to the structural and functional changes that occur in blood vessels to adapt to changes in the internal and external environment, including cell biological changes such as proliferation, hypertrophy, apoptosis, cell migration, and production and degradation of extracellular matrix in vascular wall cells. Vascular remodeling is an important pathological basis for the deterioration of many vascular-related diseases (such as transplant rejection, atherosclerosis, and hypertension) and is also the cause of the occurrence and development of such diseases.
[0106] As used herein, the terms "patient," "subject," and "individual" are used interchangeably and include humans and non-human animals, including mammals such as monkeys, rats, mice, cows, pigs, goats, sheep, dogs, and cats.
[0107] As used herein, "administering" and "treating" when referring to an animal, human, subject, cell, tissue, organ, or biological fluid, refers to contacting an exogenous drug, therapeutic agent, diagnostic agent, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid. "Administering" and "treating" can refer to, for example, therapeutic methods, pharmacokinetic methods, diagnostic methods, research methods, and experimental methods. Treating cells includes contacting an agent with a cell and contacting an agent with a fluid, wherein the fluid contacts the cell. "Administering" and "treating" also mean in vitro and ex vivo treatment of cells, for example, by an agent, diagnostic agent, binding composition, or by other cells.
[0108] As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount of the inhibitor that is effective in preventing or alleviating the disease or condition to be treated when the inhibitor is administered alone or in combination with another therapeutic agent to a cell, tissue or subject. A therapeutically effective amount further refers to an amount of the inhibitor sufficient to cause a reduction in symptoms, such as treatment, cure, prevention or alleviation of a related medical condition, or to increase the rate of treatment, cure, prevention or alleviation of the symptoms. The effective amount for a specific subject may vary depending on a variety of factors, such as the disease to be treated, the patient's overall health, the method, route and dosage of administration, and the severity of side effects. An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects. When an active ingredient is administered alone to an individual, a therapeutically effective amount refers to that single ingredient. When a combination is administered, a therapeutically effective amount refers to the combined amount of active ingredients that produces a therapeutic effect, regardless of whether it is administered in combination, sequentially or simultaneously. A therapeutically effective amount will generally alleviate symptoms by at least 10%; usually at least 20%; preferably at least about 30%; more preferably at least 40% and most preferably at least 50%.
[0109] As used herein, the term "treating" includes amelioration or cessation of a disorder or symptom thereof. Treatment includes inhibition, such as reducing the overall frequency of onset of a disorder or symptom thereof.
[0110] As used herein, the term "relieve" includes an improvement or alleviation of at least one indicator, sign or symptom of a disease or its symptoms; for example, improvement includes a delay or slowing of the progression or severity of one or more indicators of a disease or its symptoms. The progression or severity of an indicator can be determined by subjective or objective measurements known to those skilled in the art.
[0111] As used herein, the term "preventing" includes avoiding the onset of a disorder or symptoms thereof.
[0112] In this article, the term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" refers to auxiliary materials widely used in the field of drug production. The main purpose of using excipients is to provide a pharmaceutical composition that is safe to use, stable in nature and / or has specific functionality, and also to provide a method so that after the drug is administered to the subject, the active ingredient can be dissolved at a desired rate, or to promote the effective absorption of the active ingredient in the subject receiving the administration. Pharmaceutically acceptable excipients can be inert fillers or functional ingredients that provide a certain function to the pharmaceutical composition (for example, stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient in the composition). Non-limiting examples of pharmaceutically acceptable excipients include, but are not limited to, adhesives, suspending agents, emulsifiers, diluents (or fillers), granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents, sweeteners, etc.
[0113] The pharmaceutical composition of the present disclosure can be prepared using any method known to those skilled in the art. For example, conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding and / or lyophilizing processes. In some embodiments, the pharmaceutical composition of the present disclosure can be administered by any suitable route known in the art, including but not limited to: oral, nasal, intradermal, subcutaneous, intravenous, intramuscular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic and / or cerebrospinal. The route of administration can be changed or adjusted in any applicable manner to meet the needs of the properties of the drug, the convenience of the patient and medical staff, and other related factors.
[0114] As used herein, "antibody" refers to any form of an antibody that exhibits the desired biological activity. Therefore, "antibody" is used in its broadest sense and explicitly includes, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies), fully human, humanized, primatized, chimeric antibodies, single-chain antibodies, etc.
[0115] As used herein, "antigen binding fragment" refers to a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc. Regardless of its structure, an antibody fragment binds to the same antigen that is recognized by the intact antibody. The term "antigen binding fragment" includes aptamers, spiegelmers, and bivalent antibodies. The term "antigen binding fragment" also includes any synthetic or genetically engineered protein that acts as an antibody by binding to a specific antigen to form a complex.
[0116] As used herein, "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, the individual antibodies constituting the population being identical. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include a plurality of different antibodies directed against a plurality of different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
[0117] As used herein, the term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is derived from one source or species, while the remainder of the heavy chain and / or light chain is derived from a different source or species.
[0118] As used herein, the term "encoding" refers to a polynucleotide that is said to "encode" a protein if it can be transcribed and / or translated to produce mRNA of the protein and / or its fragments in its native state or when manipulated by methods well known to those skilled in the art.
[0119] As used herein, the term "identity" can be evaluated by the naked eye or by computer software (e.g., the software program described in Ausubel et al. eds. (2007) in Current Protocols in Molecular Biology). When a position in the compared sequences is occupied by the same base or amino acid, the molecules are identical at that position. The identity between two or more sequences can be expressed as a percentage (%), which can be used to evaluate the identity between related sequences. A polynucleotide sequence or amino acid sequence having a certain percentage (e.g., 90%, 95%, 98% or 99%) of "sequence identity" with another sequence means that when the sequences are aligned, the percentage of bases or amino acids in the two compared sequences are the same.
[0120] As used herein, "conservatively substituted variants" or "conservative amino acid substitutions" refer to amino acid substitutions known to those skilled in the art, which are made without generally altering the biological activity of the resulting molecule. In general, it is recognized by those skilled in the art that single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter the biological activity. Conservative substitutions can be substitutions with amino acids containing side chains with similar chemical properties, such as: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid.
[0121] As used herein, "transplant rejection" and "transplant immune rejection" are used interchangeably.
[0122] Use of type I collagen inhibitors and / or solute carrier cystine transporter inhibitors
[0123] By establishing a mouse allogeneic organ vascular transplantation model and performing picrosirius red staining analysis, it was found that type I collagen increased significantly during graft rejection. Furthermore, by intervening mouse macrophages with type I collagen and performing BODIPY staining, it was found that type I collagen can promote the generation of foam cells.
[0124] Furthermore, by intervening mouse macrophages with type I collagen and performing flow cytometry and cytopathological staining of Slc7a11, it was found that type I collagen can promote the high expression of cystine transporter Slc7a11 on the surface of macrophages.
[0125] In addition, in vitro experiments were conducted using type I collagen to intervene in mouse macrophages, and then Slc7a11 was inhibited using siRNA or Erastin and BODIPY staining was performed. It was found that inhibition of Slc7a11 could antagonize the pro-foam cell production effect of type I collagen.
[0126] In vivo experiments were also conducted. Before transplantation, mice were administered Erastin or SB525334, and F4 / 80, BODIPY and DAPI staining were performed 14 days (2 weeks) after surgery. It was found that the number of foam cells in the transplanted blood vessels was significantly reduced 14 days after surgery after the intervention of Erastin anti-Slc7a11 and SB525334 anti-type I collagen production. HE staining was performed 28 days (4 weeks) after surgery, and it was found that the degree of intimal hyperplasia and remodeling of the transplanted blood vessels was significantly reduced 28 days after surgery after the intervention of Erastin anti-Slc7a11 and SB525334 anti-type I collagen production. This indicates that inhibiting type I collagen production or inhibiting Slc7a11 protein can significantly improve vascular remodeling of transplanted organs.
[0127] Based on the above findings, the present invention provides the use of type I collagen inhibitors and / or solute carrier cystine transporter inhibitors in the preparation of products for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases (such as transplant immune rejection).
[0128] In some embodiments, the type I collagen inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, and small molecule compounds against type I collagen; wherein the nucleic acid is a small interfering RNA, dsRNA, microRNA, antisense nucleic acid, or gene editing vector (such as CRISPR-Cas9 gene editing vector or TALEN gene editing vector) that targets type I collagen or its transcript and can inhibit type I collagen expression or gene transcription. In some embodiments, the small molecule compound can be SB525334 or UK 383367.
[0129] In some embodiments, the solute carrier cystine transporter inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, and small molecule compounds directed against the solute carrier cystine transporter, wherein the nucleic acid is a small interfering RNA, dsRNA, microRNA, antisense nucleic acid, or gene editing vector (such as CRISPR-Cas9 gene editing vector or TALEN gene editing vector) that targets the solute carrier cystine transporter or its transcript and can inhibit the expression or gene transcription of the solute carrier cystine transporter. In some embodiments, the small molecule compound can be Erastin, HG106.
[0130] It is well known in the art that small interfering RNA, dsRNA, microRNA, antisense nucleic acid or gene editing vector can be used to interfere with or reduce the expression of target genes. Depending on the target gene to be acted on, those skilled in the art can easily design and select these small interfering RNA, dsRNA, microRNA, antisense nucleic acid or gene editing vector using known methods and techniques.
[0131] In some embodiments, the solute carrier cystine transporter inhibitor is siRNA-Slc7a11 consisting of SEQ ID NO:1 and SEQ ID NO:2.
[0132] Type I collagen or its encoding gene, solute carrier cystine transporter or its encoding gene as biomarkers or target
[0133] Based on the finding that the expression level of the gene encoding type I collagen, the expression level or activity of type I collagen in patients with vascular remodeling and / or vascular remodeling-related diseases (e.g., transplant immune rejection) is increased compared with a normal control group, and the expression level of the gene encoding the solute carrier cystine transporter, the expression level or activity of the solute carrier cystine transporter is increased compared with a normal control group, the present invention also provides the following uses of type I collagen or its encoding gene as a biomarker or target, an agent for detecting the type I collagen or its encoding gene, the solute carrier cystine transporter or its encoding gene as a biomarker or target, and / or an agent for detecting the type I collagen or its encoding gene:
[0134] i. Application in screening for vascular remodeling and / or diseases related to vascular remodeling or in preparing products for screening for vascular remodeling and / or diseases related to vascular remodeling;
[0135] ii. Application in evaluating vascular remodeling and / or vascular remodeling-related diseases or in preparing products for evaluating vascular remodeling and / or vascular remodeling-related diseases;
[0136] iii. Application in the preparation of products for diagnosing vascular remodeling and / or vascular remodeling-related diseases;
[0137] iv. Application in screening and / or preparing products for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases;
[0138] v. Application in monitoring the course of vascular remodeling and / or vascular remodeling-related diseases or in preparing products for monitoring the course of vascular remodeling and / or vascular remodeling-related diseases;
[0139] vi. Application in analyzing vascular remodeling and / or the prognosis of diseases related to vascular remodeling or preparing products for analyzing vascular remodeling and / or the prognosis of diseases related to vascular remodeling;
[0140] vii. Use in inhibiting foam cell formation or preparing products for inhibiting foam cell formation.
[0141] In some embodiments, the reagent is a reagent for detecting the expression amount and / or activity level of the type I collagen and / or a reagent for detecting the mRNA expression amount of a gene encoding type I collagen.
[0142] All reagents for detecting the expression amount and / or activity level of type I collagen and / or reagents for detecting the mRNA expression amount of the gene encoding type I collagen can be used for the above applications i-vii.
[0143] In some embodiments, the reagent is a reagent for detecting the expression amount and / or activity level of the solute carrier cystine transporter and / or a reagent for detecting the mRNA expression amount of a gene encoding a solute carrier cystine transporter.
[0144] All reagents for detecting the expression amount and / or activity level of the solute carrier cystine transporter and / or reagents for detecting the mRNA expression amount of the solute carrier cystine transporter encoding gene can be used for the above applications i-vii.
[0145] In some embodiments, the reagent is a reagent for detecting the expression amount of the biomarker by PCR, flow cytometry, enzyme-linked immunosorbent assay, immunofluorescence, radioimmunoassay, immunocoprecipitation, immunoblotting, high performance liquid chromatography, capillary gel electrophoresis, near infrared spectroscopy, mass spectrometry, immunochemiluminescence, colloidal gold immunoassay, fluorescent immunochromatography, surface plasmon resonance, immuno-PCR or biotin-avidin technology.
[0146] In some embodiments, the reagents are primer combinations and probes for detecting genes encoding type I collagen or genes encoding solute carrier cystine transporter.
[0147] In some embodiments, the reagent is an antibody (including primary antibody, secondary antibody) or aptamer or dye for detecting type I collagen or solute carrier cystine transporter, such as Slc7a11 antibody, PE fluorescently labeled goat anti-rabbit secondary antibody.
[0148] Vascular stents or catheters with balloons
[0149] The type I collagen inhibitor and / or solute carrier cystine transporter inhibitor of the present invention can be coated on the balloon in the vascular stent and the catheter with a balloon. By implanting such a vascular stent and the catheter with a balloon into a blood vessel, the vascular lumen channel can be maintained, blood flow can be improved, and vascular remodeling can be improved.
[0150] Pharmaceutical composition
[0151] The present invention also provides a pharmaceutical composition, which comprises an effective amount of a type I collagen inhibitor and / or a solute carrier cystine transporter inhibitor and a pharmaceutically acceptable auxiliary material.
[0152] In some embodiments, the pharmaceutical compositions of the present invention may be administered by any suitable route known in the art, including but not limited to oral, nasal, intradermal, subcutaneous, intravenous, intramuscular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic and / or cerebrospinal.
[0153] In some embodiments, the composition is formulated into a pharmaceutical composition suitable for intravenous injection in human body according to conventional steps. The composition for intravenous administration is usually a solution in a sterile isotonic aqueous buffer. The pharmaceutical composition may also include a solubilizer and a local anesthetic such as lidocaine to relieve pain at the injection site. Generally speaking, the active ingredient is supplied alone or mixed together in a unit dose form, such as in a sealed container (such as an ampoule or a pouch) that indicates the amount of active agent in the form of a dry lyophilized powder or anhydrous concentrate. In the case of administering the composition by infusion, the composition can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. In the case of administering the composition by injection, an ampoule of sterile water for injection or saline can be used so that the active ingredient can be mixed before administration.
[0154] Combination therapy
[0155] The type I collagen inhibitor and / or solute carrier cystine transporter inhibitor of the present invention can be used in combination with at least one additional therapeutic agent (e.g., contained in the same pharmaceutical composition), such as in combination with a glucocorticoid, as long as such combination can play a beneficial role in preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases (e.g., transplant rejection).
[0156] RAW264.7 mouse macrophages were obtained from ATCC cell bank, catalog number: TIB-71.
[0157] DMEM culture medium (containing sodium pyruvate) was purchased from BI, catalog number: 06-1055-57-1ACS.
[0158] Fetal bovine serum was purchased from Gibco, catalog number: 10099141C.
[0159] Phosphate buffered saline (PBS) was purchased from Jiangsu KeyGen Biotech Co., Ltd., catalog number: KGB5001.
[0160] 0.25% trypsin, purchased from Gibco, catalog number: 25200056.
[0161] Penicillin-streptomycin dual antibody was purchased from HyClone, catalog number: SV30010.
[0162] BODIPY dye, purchased from MCE, catalog number: 158757-79-0.
[0163] Col1a1 (type I collagen α1, referred to as type I collagen in the following examples) was purchased from Novus Biologicals, catalog number: P5215.
[0164] Anti-xCT antibody (referred to as Slc7a11 antibody in the following examples) was purchased from Abcam, catalog number: ab216876.
[0165] DAPI nuclear dye, purchased from Sigma-Aldrich, catalog number: 28718-90-3.
[0166] PE fluorescently labeled goat anti-rabbit secondary antibody was purchased from Beijing Solebow Technology Co., Ltd., catalog number: K0034G-PE.
[0167] Bovine serum albumin (BSA) was purchased from Shanghai Huiying Biotechnology Co., Ltd., catalog number: 738328.
[0168] Erastin (ferroptosis inducer) was purchased from MCE, catalog number: 571203-78-6.
[0169] SB525334 (type I collagen α1 and type I collagen α3 inhibitor) was purchased from MCE, catalog number: 356559-20-1.
[0170] Lipofectamine TM 3000, purchased from ThermoFisher, catalog number: L3000001.
[0171] The sequence of siRNA-Slc7a11 is as follows:
[0172] Sense strand: 5'-CCGGAAAUCCUCUCUAUGATT-3' (SEQ ID NO: 1)
[0173] Antisense strand: 5'-UCAUAGAGAGGAUUUCCGGTT-3' (SEQ ID NO: 2).
[0174] Eosin staining solution was purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., catalog number: C0109.
[0175] Hematoxylin staining solution was purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., product number: C0107-100ml.
[0176] APC fluorescent anti-mouse F4 / 80 antibody was purchased from BioLegand, catalog number: 123116.
[0177] Example 1: A large amount of type I collagen exists in the blood vessels of transplanted organs and type I collagen promotes the differentiation of macrophages into foam cells
[0178] (I) There is a large amount of type I collagen in the blood vessels of transplanted organs
[0179] Experimental Animals:
[0180] Male C57BL / 6 mice and BALB / C mice, all 8 weeks old and weighing 18-22 g, were provided by Hunan Slake Jingda Experimental Animal Co., Ltd. The experimental conditions were SPF grade, room temperature 20-24°C, relative humidity 50%-60%, ventilation in independent ventilation cages, light 12 hours / day, caged, 6 mice per cage, and cages cleaned once a week.
[0181] Experimental methods:
[0182] 1. Six 8-week-old male C57BL / 6 mice were selected and a sham incision was made on the left neck of the carotid artery to be sutured as the control group; the aortas of six 8-week-old male BALB / C mice were transplanted into the carotid arteries of the left neck of six 8-week-old male C57BL / 6 mice to construct an allogeneic organ vascular transplantation model as the transplantation group. Two weeks after surgery, the aortic tissues of the control group and the transplanted aortic tissues of the transplantation group were fixed and frozen and stained with picrosirius red.
[0183] 2. Fixation of frozen sections: Add 4% paraformaldehyde to the aorta tissue and fix it at 4°C for 6 hours. Wash the tissue three times with 1×PBS and place it in a mold with OCT embedding agent to immerse the tissue. Then slowly place the mold flat in a small cup filled with liquid nitrogen. After 10-20 seconds, take out the mold and store it in a -80°C refrigerator. Use a constant temperature freezing slicer to continuously slice the tissue into thin slices of 6μm, and attach the tissue sections to glass slides.
[0184] 3. Sirius red staining: Add Sirius red staining solution to the tissue section for 20 minutes, then add hematoxylin staining solution for 5 minutes, rinse with running water for 2-5 minutes, seal with neutral gum, and observe the distribution of type I collagen under a polarized light microscope (Olympus BX51).
[0185] The experimental results showed that the type I collagen detected in the graft vascular tissue of the allogeneic organ vascular transplantation model mice was significantly higher than that in the control group. Figure 1 As shown in A and B, the content of type I collagen in the transplanted vascular tissue increased significantly after transplantation (P<0.0001), and the content of type I collagen in each field of view of the transplanted mice was 20.55 times that of the control group (FC (difference fold) = 20.55, P = 0.0048). This indicates that type I collagen increases significantly during transplant rejection and is related to the development of transplant rejection.
[0186] (II) Type I collagen promotes the differentiation of macrophages into foam cells
[0187] RAW264.7 mouse macrophages were cultured in DMEM medium containing 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin. One day before intervention, the bottom of the 6-well plate in the type I collagen intervention group was smeared with type I collagen acetic acid solution (type I collagen was dissolved in 0.02N acetic acid aqueous solution to saturation, dissolved overnight and filtered to remove undissolved type I collagen the next day), and the bottom of the 6-well plate in the control group was smeared with acetic acid solution (0.02N acetic acid aqueous solution), and irradiated with ultraviolet light overnight in a sterile ventilated operating table until the acetic acid solvent was air-dried. The next day, RAW264.7 mouse macrophages were cultured in DMEM medium containing 10% (v / v) fetal bovine serum and without penicillin-streptomycin, and the seed plate (6×10 5 cells / well). After 24 hours of seeding, the cell density reached 50-60%, the culture medium was discarded, and the cells were gently rinsed once with 1×PBS. BODIPY dye was diluted 1:2000 in 1×PBS, and 40 μL was added to each well and incubated with the cells for 20 min. After washing 3 times with 1×PBS, the cells were photographed and observed under a fluorescence microscope.
[0188] The results are as follows Figure 1 As shown in C and D.
[0189] The experimental results showed that compared with the control group, there was a large amount of green fluorescence after lipid staining in the macrophages of RAW264.7 mice in the type I collagen intervention group, indicating that the cell phenotype changed to foam cells, indicating that type I collagen can promote the formation of foam cells.
[0190] Example 2 Type I collagen promotes the expression of the solute carrier cystine transporter on the macrophage membrane
[0191] 1. RAW264.7 mouse macrophages were cultured in DMEM medium containing 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin dual antibody; one day before the intervention, the bottom of the 6-well plate in the type I collagen intervention group was smeared with type I collagen acetic acid solution (same as in Example 1), and the bottom of the 6-well plate in the control group was smeared with acetic acid solution (same as in Example 1), and ultraviolet irradiation was carried out overnight in a sterile ventilated operating table until the acetic acid solvent was air-dried. The next day, RAW264.7 mouse macrophages were cultured in DMEM medium containing 10% (v / v) fetal bovine serum and no penicillin-streptomycin, and the seed plate (6×10 5 cells / well).
[0192] 2. Flow staining and detection: When the culture density of type I collagen intervention group and control group in 6-well plate was about 70%, 0.25% trypsin was used for digestion at 37℃ for 2min, and then washed with 1×PBS until the cells were suspended. After centrifugation at 4℃ and 400rcf for 7 minutes, the supernatant was removed. After Slc7a11 antibody was diluted 1:100 in 1×PBS, 100μL antibody diluent was added to each well and incubated with cells for 40min, and then washed with 1×PBS to 500μL. After centrifugation at 4℃ and 400rcf for 7 minutes, the supernatant was removed and repeated 3 times. After washing, the cells were incubated with PE fluorescent labeled goat anti-rabbit secondary antibody diluent (diluted with 1×PBS 1:200) for 20 minutes. After centrifugation at 4℃ and 400rcf for 7 minutes, the supernatant was removed and diluted to 500μL with 1×PBS, and the content of cell membrane Slc7a11 protein was detected by flow cytometry.
[0193] 3. Pathological immunofluorescence staining and detection: When the culture density of type I collagen intervention group and control group in 6-well plate was about 60%, the remaining culture medium was removed and washed with 1×PBS for 3 times. 4% paraformaldehyde was fixed for 15 minutes, and the slides were immersed in 1×PBS for 3 times, each time for 3 minutes, and then blocked with 5% BSA solution at room temperature for 30 minutes. The blocking solution was removed, and the Slc7a11 antibody was diluted 1:50 in 1×PBS and dropped on the slides. The slides were incubated in a wet box at 4°C overnight. The supernatant was washed the next day, and the PE fluorescent-labeled goat anti-rabbit secondary antibody dilution (diluted with 1×PBS 1:100) was incubated for 1 hour, and then the supernatant was removed. DAPI was added and incubated in the dark for 5 minutes, and the excess DAPI was washed with PBST for 5 minutes × 4 times, and the images were collected under a fluorescence microscope.
[0194] The results are as follows Figure 2 shown.
[0195] The experimental results showed that the flow cytometry results showed that the fluorescence signal intensity of Slc7a11 on the cell membrane in the type I collagen intervention group was significantly increased compared with the control group ( Figure 2 A and B), cytopathological immunofluorescence staining results showed that cells after type I collagen intervention expressed more Slc7a11 ( Figure 2 C and D). This indicates that type I collagen can promote the high expression of cystine transporter Slc7a11 on the surface of macrophages.
[0196] Example 3 In vitro experiments demonstrate that inhibition of cystine transporter can antagonize the effect of type I collagen on promoting foam cell formation
[0197] 1. RAW264.7 mouse macrophages were cultured in DMEM medium containing 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin dual antibody; one day before intervention, the bottom of the 6-well plate in the type I collagen intervention group was coated with type I collagen acetic acid solution (same as in Example 1), and the bottom of the 6-well plate in the non-collagen intervention group was coated with acetic acid solution (same as in Example 1), and ultraviolet irradiation was performed overnight in a sterile ventilated operating table until the acetic acid solvent was air-dried. The next day, RAW264.7 mouse macrophages were cultured in DMEM medium containing 10% (v / v) fetal bovine serum and no penicillin-streptomycin, and the seed plate (6×10 5 cells / well).
[0198] 2. Setting of siRNA-Slc7a11 transfection group, anti-Slc7a11 intervention group and control group
[0199] siRNA-Slc7a11 transfection group: Transfect the two groups of cells in step 1 with siRNA-Slc7a11: When the cells grow to a density of 50%, dilute siRNA-Slc7a11 with 1×PBS to a 100μM siRNA stock solution, and prepare 125μL siRNA dilution solution by adding 10μL siRNA stock solution + 115μL DMEM medium. 9.6μL lipofectamine TM 3000+115.4μL DMEM medium was used to prepare 125μL of Lipo3000 dilution. 125μL of siRNA dilution and Lipo3000 dilution were mixed and incubated for 15min to prepare transfection mixture. The cell culture medium in the wells was removed, and 2mL of DMEM medium was added after washing 3 times with 1×PBS. 50μL of transfection mixture was added to each well for transfection for 12h. After 12h, it was replaced with DMEM medium containing 10% (v / v) fetal bovine serum and cultured for 48h.
[0200] Anti-Slc7a11 group: a culture medium containing 10 μM Erastin was prepared using DMEM culture medium containing 10% (v / v) fetal bovine serum, and the two groups of cells in step 1 were cultured to a density of 70%.
[0201] Control group: The two groups of cells in step 1 were cultured to 70% density using DMEM medium containing 10% (v / v) fetal bovine serum.
[0202] 3. BODIPY staining: discard the culture medium of the cells in the siRNA-Slc7a11 transfection group, anti-Slc7a11 group and control group, gently rinse the cells once with 1×PBS, dilute BODIPY dye 1:2000 in 1×PBS, add 40 μL to each well and incubate with the cells for 20 min, then wash with 1×PBS for 3 times and observe under a fluorescence microscope.
[0203] The results are as follows Figure 3 shown.
[0204] The experimental results showed that in the control group, compared with the group without collagen intervention, the green fluorescence of lipid staining in the RAW264.7 mouse macrophages in the group with type I collagen intervention was large, indicating that the cell phenotype changed to foam cells, indicating that type I collagen can promote the formation of foam cells. However, in the anti-Slc7a11 group and the siRNA-Slc7a11 transfection group, the lipid green fluorescence in the RAW264.7 mouse macrophages after type I collagen intervention did not increase significantly compared with the group without collagen intervention ( Figure 3 (A and B), indicating that inhibition of Slc7a11 can antagonize the foam cell-promoting effect of type I collagen.
[0205] Example 4 In vivo experiments demonstrate that inhibition of type I collagen and inhibition of cystine transporter can both reduce foam cell generation and improve graft vascular remodeling
[0206] Experimental Animals:
[0207] Male C57BL / 6 mice and BALB / C mice, all 8 weeks old and weighing 18-22 g, were provided by Hunan Slake Jingda Experimental Animal Co., Ltd. The experimental conditions were SPF grade, room temperature 20-24°C, relative humidity 50%-60%, ventilation in independent ventilation cages, light 12 hours / day, caged, 6 mice per cage, and cages cleaned once a week.
[0208] 1. Twelve 8-week-old male C57BL / 6 mice were intraperitoneally injected with Erastin (10 mg / kg, dissolved in 1×PBS, injection volume of 400 μL) every day from 1 week before the transplantation model was established until samples were collected on the 14th and 28th days after the transplantation operation, as the anti-Slc7a11 group; Twelve 8-week-old male C57BL / 6 mice were intraperitoneally injected with SB525334 (30 mg / kg, dissolved in 1×PBS, injection volume of 400 μL) every day from 1 week before the transplantation model was established until samples were collected on the 14th and 28th days after the transplantation operation, as the anti-type I collagen group; Twelve 8-week-old male C57BL / 6 mice were intraperitoneally injected with 1×PBS (20 mL / kg) every day from 1 week before the transplantation model was established until samples were collected on the 14th and 28th days after the transplantation operation, as the control group. All three groups of mice underwent allogeneic organ vascular transplantation using the same method as in Example 1 for establishing an allogeneic organ vascular transplantation model.
[0209] 2. Frozen sections of graft blood vessels and pathological immunofluorescence staining and HE staining:
[0210] Pathological immunofluorescence staining: Take the graft blood vessels of each group of mice 14 days (2 weeks) after surgery to prepare frozen pathological sections (preparation method is the same as the fixed frozen sections in Example 1). The frozen tissue sections were placed at room temperature for 10 minutes, and the sections were warmed up and dried. The OCT was washed off with 1×PBS for 10 minutes, fixed with 4% paraformaldehyde for 1 minute, and then gently rinsed 3 times with 1×PBS, and blocked with 5% BSA solution at room temperature for 30 minutes. APC fluorescent anti-mouse F4 / 80 antibody dilution (diluted with 1×PBS 1:200) was added, and incubated at 4°C overnight, protected from light. After washing the dilution with 1×PBS, incubate with BODIPY dilution (diluted with 1×PBS 1:2000) for 30 minutes, then wash the incubation solution, and then incubate with 1×PBS dilution with a concentration of 0.1μg / mL DAPI for 1 minute, then rinsed 3 times with 1×PBS, and observed under a fluorescence microscope after sealing with anti-fluorescence quencher resin.
[0211] HE staining: Take the graft blood vessels of each group of mice 28 days (4 weeks) after surgery to prepare frozen pathological sections (preparation method is the same as the fixed frozen sections in Example 1). Place the frozen tissue sections at room temperature for 10 minutes, wait for the sections to return to temperature and dry, wash off the OCT with 1×PBS for 10 minutes, fix with 4% paraformaldehyde for 1 minute, and then gently rinse with 1×PBS 3 times. The slides are immersed in a dyeing jar containing hematoxylin for about 5 minutes, and then the hematoxylin is washed off with clean water. The slides are immersed in 1% hydrochloric acid ethanol for 2 seconds, then rinsed with clean water for 1-2 seconds, and 1% ammonia water is blued for 10 seconds. After rinsing with clean water for 2 seconds, the slides are immersed in a dyeing jar containing eosin for 40 seconds. The slides are placed in three jars of anhydrous ethanol, 90% ethanol, and 75% ethanol in turn for 4 minutes each, and then permeabilized with xylene for 4 minutes. Finally, the slides are sealed with resin and observed and photographed under an upright microscope.
[0212] The results are as follows Figure 4 shown.
[0213] Results: Pathological immunofluorescence staining results showed that the number of foam cells in transplanted blood vessels after Erastin anti-Slc7a11 intervention and SB525334 anti-type I collagen production intervention was significantly lower than that in the control group 14 days after surgery ( Figure 4 HE staining results showed that the degree of intimal hyperplasia and remodeling of transplanted blood vessels after Erastin anti-Slc7a11 intervention and SB525334 anti-type I collagen production intervention was significantly milder than that of the control group 28 days after surgery ( Figure 4 This indicates that inhibiting type I collagen production or inhibiting Slc7a11 protein can significantly improve vascular remodeling of transplanted organs.
[0214] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0215] The above-mentioned embodiments only express several implementation methods of the present disclosure, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present disclosure, and these all belong to the protection scope of the present disclosure. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims.
Claims
1. Use of type I collagen inhibitors and / or solute carrier cystine transporter inhibitors in the preparation of products for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases.
2. The use according to claim 1, characterized in that: The type I collagen is Col1a1; The solute carrier cystine transporter is Slc7a11; Preferably, the type I collagen inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, and small molecule compounds against type I collagen; The solute carrier cystine transporter inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, and small molecule compounds against the solute carrier cystine transporter.
3. The use according to claim 1 or 2, characterized in that: The vascular remodeling is vascular remodeling associated with a vascular-related disease or condition; Preferably, the disease or condition is selected from vascular wall damage, post-injury vascular stenosis, post-injury blood flow dysfunction, thrombosis, post-PCI and Bypass vascular stenosis, atherosclerosis, cerebral infarction, transplant vascular disease after allogeneic transplantation, transplant rejection, diabetic microangiopathy, cerebrovascular disease and any combination thereof.
4. The following uses of type I collagen or its encoding gene as a biomarker or target, an agent for detecting said type I collagen or its encoding gene, a solute carrier cystine transporter or its encoding gene as a biomarker or target and / or an agent for detecting said solute carrier cystine transporter or its encoding gene: i. Application in screening for vascular remodeling and / or diseases related to vascular remodeling or in preparing products for screening for vascular remodeling and / or diseases related to vascular remodeling; ii. Application in evaluating vascular remodeling and / or vascular remodeling-related diseases or in preparing products for evaluating vascular remodeling and / or vascular remodeling-related diseases; iii. Application in the preparation of products for diagnosing vascular remodeling and / or vascular remodeling-related diseases; iv. Application in screening and / or preparing products for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases; v. Application in monitoring the course of vascular remodeling and / or vascular remodeling-related diseases or in preparing products for monitoring the course of vascular remodeling and / or vascular remodeling-related diseases; vi. Application in analyzing vascular remodeling and / or the prognosis of diseases related to vascular remodeling or in preparing products for analyzing vascular remodeling and / or the prognosis of diseases related to vascular remodeling; vii. Use in inhibiting foam cell formation or preparing products for inhibiting foam cell formation.
5. The use according to claim 4, characterized in that: The reagent for detecting the type I collagen or its encoding gene is a reagent for detecting the expression amount and / or activity level of the type I collagen and / or a reagent for detecting the mRNA expression amount of the type I collagen encoding gene; The reagent for detecting the solute carrier cystine transporter or its encoding gene is a reagent for detecting the expression amount and / or activity level of the solute carrier cystine transporter and / or a reagent for detecting the mRNA expression amount of the solute carrier cystine transporter encoding gene; Preferably, the reagents include reagents for detecting the expression amount of the biomarker by PCR, flow cytometry, enzyme-linked immunosorbent assay, immunofluorescence, radioimmunoassay, immunocoprecipitation, immunoblotting, high performance liquid chromatography, capillary gel electrophoresis, near infrared spectroscopy, mass spectrometry, immunochemiluminescence, colloidal gold immunoassay, fluorescent immunochromatography, surface plasmon resonance, immuno-PCR or biotin-avidin technology; Preferably, the type I collagen is Col1a1; The solute carrier cystine transporter is Slc7a11.
6. The use according to claim 4 or 5, characterized in that: The expression level of the gene encoding type I collagen, the expression level or activity of type I collagen in patients with vascular remodeling and / or vascular remodeling-related diseases is increased compared with a normal control group; and / or In patients with vascular remodeling and / or vascular remodeling-related diseases, the expression level of the solute carrier cystine transporter encoding gene, the expression level or activity of the solute carrier cystine transporter is increased compared with the normal control group.
7. The use according to any one of claims 4 to 6, characterized in that: The vascular remodeling is vascular remodeling associated with a vascular-related disease or condition; Preferably, the disease or condition is selected from vascular wall damage, post-injury vascular stenosis, post-injury blood flow dysfunction, thrombosis, post-PCI and Bypass vascular stenosis, atherosclerosis, cerebral infarction, transplant vascular disease after allogeneic transplantation, transplant rejection, diabetic microangiopathy, cerebrovascular disease and any combination thereof.
8. A method for screening drugs for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases, comprising: Selecting a substance that inhibits type I collagen and / or a substance that inhibits the solute carrier cystine transporter from the compounds to be screened as a drug for preventing, treating and / or alleviating vascular remodeling and / or vascular remodeling-related diseases; Preferably, the type I collagen is Col1a1; The solute carrier cystine transporter is Slc7a11.
9. The method according to claim 8, characterized in that: The vascular remodeling is vascular remodeling associated with a vascular-related disease or condition; Preferably, the disease or condition is selected from vascular wall damage, post-injury vascular stenosis, post-injury blood flow dysfunction, thrombosis, post-PCI and Bypass vascular stenosis, atherosclerosis, cerebral infarction, transplant vascular disease after allogeneic transplantation, transplant rejection, diabetic microangiopathy, cerebrovascular disease and any combination thereof.
10. A product comprising or coated with an effective amount of a type I collagen inhibitor and / or a solute carrier cystine transporter inhibitor; Preferably, the type I collagen is Col1a1; The solute carrier cystine transporter is Slc7a11; Preferably, the type I collagen inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, and small molecule compounds against type I collagen; The solute carrier cystine transporter inhibitor is selected from one or more of the following: antibodies or antigen-binding fragments thereof, nucleic acids, and small molecule compounds against the solute carrier cystine transporter; Preferably, the product is a vascular stent or a catheter with a balloon; or The product is a pharmaceutical composition, which comprises the type I collagen inhibitor and / or the solute carrier cystine transporter inhibitor as active ingredients, and optionally further comprises pharmaceutically acceptable excipients.
Citation Information
Cited By
ALDH1A2 inhibitor and application of reagent for detecting ALDH1A2 or RA
CN120789268A
Use of ALDH1A2 inhibitors and agents that detect ALDH1A2 or RA
CN120789268B
Application of STAT1 inhibitor and detection preparation and construction method of vascular transplantation reconstruction model
CN121796597A
